2024
Renal Cell Carcinoma of Variant Histology: New Biologic Understanding Leads to Therapeutic Advances.
Salgia N, Zengin Z, Pal S, Dizman N. Renal Cell Carcinoma of Variant Histology: New Biologic Understanding Leads to Therapeutic Advances. American Society Of Clinical Oncology Educational Book 2024, 44: e438642. PMID: 38776514, PMCID: PMC11235416, DOI: 10.1200/edbk_438642.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCarcinoma, Renal CellHumansImmune Checkpoint InhibitorsKidney NeoplasmsMolecular Targeted TherapyConceptsRenal cell carcinomaPapillary renal cell carcinomaBiology of renal cell carcinomaHistology renal cell carcinomaPatient populationRenal cell carcinoma histologyMetastatic renal cell carcinomaRenal cell carcinoma casesOptimization of treatment regimensNon-clear cellPrecision oncology approachesDiagnosed solid tumorsSarcomatoid dedifferentiationVariant histologyRare subtypeHistopathological subtypesCell carcinomaSolid tumorsClinical featuresTreatment regimensClinical findingsOncology approachesTherapeutic advancesTherapeutic approachesUnique pathogeneses
2023
Association Between Time-of-Day of Immune Checkpoint Blockade Administration and Outcomes in Metastatic Renal Cell Carcinoma
Dizman N, Govindarajan A, Zengin Z, Meza L, Tripathi N, Sayegh N, Castro D, Chan E, Lee K, Prajapati S, Feng M, Loo V, Pace M, O'Brien S, Bailey E, Barragan-Carrillo R, Chehrazi-Raffle A, Hsu J, Li X, Agarwal N, Pal S. Association Between Time-of-Day of Immune Checkpoint Blockade Administration and Outcomes in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer 2023, 21: 530-536. PMID: 37495481, DOI: 10.1016/j.clgc.2023.06.004.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, ImmunologicalCarcinoma, Renal CellHumansImmune Checkpoint InhibitorsKidney NeoplasmsNivolumabProspective StudiesRetrospective StudiesConceptsMetastatic renal cell carcinomaObjective response rateTreatment failureRenal cell carcinomaHazard ratioOverall survivalCell carcinomaMultivariate analysisHigh Cut-OffNivolumab/ipilimumabProspective Randomized StudyBaseline characteristicsRandomized studyClinical outcomesMedian timePreclinical evidenceUnivariate analysisPatientsResponse rateImmune systemInfusion timeStatistical significanceOutcomesCarcinomaInfusionUltrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma
Chehrazi-Raffle A, Muddasani R, Dizman N, Hsu J, Meza L, Zengin Z, Malhotra J, Chawla N, Dorff T, Contente-Cuomo T, Dinwiddie D, McDonald B, McDaniel T, Trent J, Baehner F, Murtaza M, Pal S. Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma. JCO Precision Oncology 2023, 7: e2200543. PMID: 37027813, PMCID: PMC10309555, DOI: 10.1200/po.22.00543.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Renal CellCirculating Tumor DNAHumansImmunotherapyKidney NeoplasmsNivolumabPilot ProjectsConceptsMetastatic renal cell carcinomaPartial responseComplete responseVariant allele fractionRenal cell carcinomaCell carcinomaCtDNA analysisImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyDiscontinuation of immunotherapyDepth of responseICI therapyNivolumab monotherapyEligible patientsRadiographic progressionInhibitor therapyPeripheral bloodDisease progressionCtDNA assessmentSubsequent progressionPatientsMultiple indicationsSingle time pointPatient-specific mutationsSecondary objectiveTwelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis
Meza L, Zengin Z, Salgia S, Malhotra J, Karczewska E, Dorff T, Tripathi A, Ely J, Kelley E, Mead H, Hsu J, Dizman N, Salgia N, Chawla N, Chehrazi-Raffle A, Muddasani R, Govindarajan A, Rock A, Liu S, Salgia R, Trent J, Altin J, Pal S. Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis. The Oncologist 2023, 28: e748-e755. PMID: 36971500, PMCID: PMC10485287, DOI: 10.1093/oncolo/oyad067.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccinationGenitourinary cancersRenal cell carcinomaBooster doseCell carcinomaImmune responseBlood samplesSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2T-cell receptor sequencingRespiratory syndrome coronavirus 2Baseline blood samplesMajority of patientsMinority of patientsProspective cohort analysisSyndrome coronavirus 2Twelve-month followAntibody titer analysisCOVID-19 vaccineSeroconversion ratesMedian ageUrothelial cancerCoronavirus 2Prostate cancerCohort analysisGenomic and Transcriptomic Predictors of Response from Stereotactic Body Radiation Therapy in Patients with Oligoprogressive Renal Cell Carcinoma
Zengin Z, Govindarajan A, Salgia N, Sayegh N, Tripathi N, Muddasani R, Chehrazi-Raffle A, Feng M, Mercier B, Ladbury C, Hao C, Salgia S, Chawla N, Meza L, Malhotra J, Dizman N, Hsu J, Castro D, Barragan-Carrillo R, Ebrahimi H, Philip E, Chang M, Zhang J, Byron S, Lyou Y, Dorff T, Pal S, Dandapani S. Genomic and Transcriptomic Predictors of Response from Stereotactic Body Radiation Therapy in Patients with Oligoprogressive Renal Cell Carcinoma. European Urology Oncology 2023, 6: 447-450. PMID: 36609061, DOI: 10.1016/j.euo.2022.11.006.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaStereotactic body radiation therapyRenal cell carcinomaBody radiation therapyCell carcinomaRadiation therapyClear cell renal cell carcinomaFirst-line treatmentCell renal cell carcinomaStereotactic body radiotherapyKidney cancer patientsOligoprogressive diseaseSystemic treatmentReactive oxygen species pathwayBody radiotherapyCancer patientsTreatment selectionPatientsTreatment changesOxygen species pathwayRadiation treatmentCarcinomaCell proliferationPotential roleRadiotherapy
2022
Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer
Zengin Z, Pal S, McDermott D, Escudier B, Hutson T, Porta C, Verzoni E, Atkins M, Kasturi V, Rini B. Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer. Clinical Genitourinary Cancer 2022, 20: 553-557. PMID: 36096984, DOI: 10.1016/j.clgc.2022.08.005.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaRenal cell carcinomaDose modificationSorafenib armAdverse eventsCell carcinomaVascular endothelial growth factor receptor inhibitorEndothelial growth factor receptor inhibitorImproved progression-free survivalGrowth factor receptor inhibitorsProgression-free survivalDuration of toxicityMeasurable diseaseOpen labelFree survivalPrimary endpointTreatment discontinuationTreatment armsReceptor inhibitorsDose reductionKidney cancerTRAEsPatientsTivozanibSorafenibNivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
Dizman N, Meza L, Bergerot P, Alcantara M, Dorff T, Lyou Y, Frankel P, Cui Y, Mira V, Llamas M, Hsu J, Zengin Z, Salgia N, Salgia S, Malhotra J, Chawla N, Chehrazi-Raffle A, Muddasani R, Gillece J, Reining L, Trent J, Takahashi M, Oka K, Higashi S, Kortylewski M, Highlander SK, Pal SK. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nature Medicine 2022, 28: 704-712. PMID: 35228755, PMCID: PMC9018425, DOI: 10.1038/s41591-022-01694-6.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Renal CellDietary SupplementsFemaleHumansIpilimumabKidney NeoplasmsMaleNivolumabConceptsMetastatic renal cell carcinomaProgression-free survivalRenal cell carcinomaCell carcinomaCheckpoint inhibitorsResponse rateGut microbiomePoor-risk diseaseTreatment-naive patientsSingle-center studyPhase 1 trialRandomized phase 1 trialSignificant differencesBifidobacterium sppMechanism of actionNivolumab-ipilimumabSarcomatoid histologyPrimary endpointSecondary endpointsImmune compartmentStudy armsClinical outcomesClear cellsClinical observationsPatients
2021
Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma
Zengin ZB, Weipert C, Salgia NJ, Dizman N, Hsu J, Meza L, Chehrazi-Raffle A, Muddasani R, Salgia S, Malhotra J, Chawla N, Philip EJ, Kiedrowski L, Maughan BL, Rathi N, Goel D, Choueiri TK, Agarwal N, Pal SK. Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma. Clinical Cancer Research 2021, 27: 4807-4813. PMID: 34130999, DOI: 10.1158/1078-0432.ccr-21-0572.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinoma, Renal CellCirculating Tumor DNAFemaleGenomeHumansKidney NeoplasmsMaleMiddle AgedMutationYoung AdultConceptsMetastatic renal cell carcinomaCell-free tumor DNARenal cell carcinomaGenomic profilingCell carcinomaTissue-based testingTumor DNA (ctDNA) assessmentClinical Laboratory Improvement AmendmentsActionable alterationsCtDNA profilingCtDNA assessmentPatientsTumor DNAUnique alterationsAlteration frequencyCarcinomaDNA assessmentBloodGreater temporal separationTissueAlterationsConcordancePrevious findingsMutationsConcordance analysis
2020
Immune Related Adverse Events: Classification and Management Approaches in Advanced Kidney Cancer.
Zengin Z, Salgia N, Chehrazi-Raffle A, Meza L, Malhotra J, Pal S. Immune Related Adverse Events: Classification and Management Approaches in Advanced Kidney Cancer. The Cancer Journal 2020, 26: 432-440. PMID: 32947311, DOI: 10.1097/ppo.0000000000000473.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Renal CellHumansImmune Checkpoint InhibitorsKidney NeoplasmsVascular Endothelial Growth Factor AConceptsImmune checkpoint inhibitorsMetastatic renal cell carcinomaRenal cell carcinomaCheckpoint inhibitorsAdverse eventsCell carcinomaDeath ligand 1 (PD-L1) immune checkpoint inhibitorsAnti-programmed death-1/Common immune-related adverse eventsImmune-related adverse eventsPivotal phase III trialsPrevious treatment optionsPhase III trialsDeath-1/Advanced kidney cancerRecent therapeutic advancementsUnique toxicity profileDrug Administration approvalFrontline regimensIII trialsClinical outcomesTreatment optionsRare toxicityAdministration approvalTargeted therapy